Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein
Yanling Song, Jia Song, Xinyu Wei, Mengjiao Huang, Miao Sun, Lin Zhu, Bingqian Lin, Haicong Shen, Zhi Zhu, Chaoyong Yang
Abstract
values of the optimized CoV2-RBD-1C and CoV2-RBD-4C aptamers against RBD were 5.8 nM and 19.9 nM, respectively. Simulated interaction modeling, along with competitive experiments, suggests that two aptamers may have partially identical binding sites at ACE2 on SARS-CoV-2 RBD. These aptamers present an opportunity for generating new probes for recognition of SARS-CoV-2 and could provide assistance in the diagnosis and treatment of SARS-CoV-2 while providing a new tool for in-depth study of the mechanisms behind the coronavirus infection.
Topics & Concepts
AptamerSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusChemistryCoronavirus disease 2019 (COVID-19)Computational biologyGlycoproteinPlasma protein bindingCompetitive binding2019-20 coronavirus outbreakVirologyBinding siteOutbreakReceptorMolecular biologyBiochemistryBiologyInfectious disease (medical specialty)MedicineDiseasePathologyAdvanced biosensing and bioanalysis techniquesSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing